A new clinical trial conducted in Malaysia has found that an eight-week regimen of ravidasvir and sofosbuvir is just as safe and effective as the standard 12-week treatment for chronic hepatitis C.
This finding could accelerate efforts to scale up access to treatment in resource-limited settings by reducing treatment duration, costs and system burden.
